Morgan Stanley analyst Erin Wright raised the firm’s price target on Cencora (COR) to $313 from $288 and keeps an Equal Weight rating on the shares following what the firm calls “another standout” quarter. U.S. Healthcare exceeded expectations yet again, which largely contributed to the FY25 EPS increase, says the analyst, who points out that this marks the fourth time Cencora has raised EPS guidance since issuing in November as the segment continually surpasses plan.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target raised to $350 from $314 at Baird
- Cencora price target raised to $355 from $330 at Citi
- Cencora’s Mixed Performance: Strong U.S. Growth Offset by International Challenges and Strategic Caution
- Cencora, Inc. Reports Strong Q2 2025 Results
- Cencora’s Earnings Call: Strong Growth Amid Challenges